anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Twin pregnancies are associated with a high risk of perinatal mortality and morbidity. Late preterm or early term delivery is frequently performed to avoid unexpected fetal death in uncomplicated twin pregnancies. Nonetheless, delivery before full term is associated with neonatal respiratory complications. This study aimed to evaluate perinatal respiratory complications in twins delivered between 36 and 38 weeks of gestation.
METHODS: A retrospective cohort study was conducted on twins delivered between 36 and 38 weeks of gestation from January 2008 to June 2020. The primary outcomes were the incidence of composite neonatal respiratory morbidity, which included respiratory distress syndrome, transient tachypnea of the newborn, meconium aspiration syndrome, mechanical ventilation or continuous positive airway pressure according to gestational age at delivery, and chorionicity. The relationship between gestational age at delivery and composite neonatal respiratory morbidity was evaluated using multivariate logistic regression analysis adjusted for potential confounders.
RESULTS: This study included 1608 twins (614 monochorionic diamniotic twins, 994 dichorionic diamniotic twins). At 36, 37, and 38 weeks of gestation, the frequencies of composite neonatal respiratory morbidity were 19.4%, 10.7%, and 9.2% in dichorionic diamniotic twins and 13.6%, 8.7%, and 9.4% in monochorionic diamniotic twins, respectively. In dichorionic diamniotic twins, the composite neonatal respiratory morbidity rate was higher for twins delivered at 36 weeks of gestation than for those delivered at 37 weeks. No significant differences between monochorionic diamniotic twins were detected.
CONCLUSIONS: In uncomplicated dichorionic diamniotic twin pregnancies, delivery should be considered after 37 weeks of gestation to reduce neonatal respiratory complications.
Eligible participants will receive GIR for up to 8 weeks. The treatment period will consist of study product administration from day 0 through day 56 with a masked dose-escalation period from day 0 through day 49.
PURPOSE: A pharmaceutical formulation is provided to enable time different absorption of drug in the human body and ensure maximal drug concentration in optimal time of drug. CONSTITUTION: A pharmaceutical formulation contains an immediate release compartment and an extended release compartment. The immediate release contains a telmisartan as an active ingredient. The extended release compartment contains an amlodipine as an active ingredient. 85 % of telmisartan of immediate release compartment is released within two hour after releasing. 0-30% of amlodipine is released four hour after releasing the telmisartan.
The invention discloses a drug, which contains purely natural traditional Chinese medicine for remedying the chronic obstructive pulmonary disease with the syndrome of qi deficiency of lung and kidney caused by the mutual obstruction of phlegm and stasis. The drug is a medical dosage which is prepared by the raw materials with the following weight portions of 2 to 8 portions of yam rhizomes, 4 to 8 portions of epimedium herbs, 8 portions of ephedra, 2 to 8 portions of bitter apricot nuts, 2 to 8 portions of magnolia officinals, 4 to 16 portions of danshen roots, 4 to 16 portions of dried milkvetch roots, 2 to 8 portions of gingers and 1 to 4 portions of liquorice roots. The drug of the invention has the functions of dispersing lung qi to send down the upward adverse flow of qi, eliminating phlegm, relieving dyspnea and reinforcing kidney to enhance the body resistance. The drug of the invention is applicable to the patient with the syndrome of qi deficiency of lung and kidney caused by the mutual obstruction of phlegm and stasis and has accurate and significant curative effect of remedying the chronic bronchitis with low recrudescence rate, and no adverse reaction occurs. The research of toxicology and pharmacodynamics completely testifies the safety of the drug of the invention and the wide pharmacological effects of the drug of the invention of relieving a cough, eliminating phlegm, relieving asthma, resisting inflammation etc. In addition, the invention also discloses the preparation method of the drug.
Puzzles, which are among the active learning tools, are frequently preferred today because they make learning fun, are economical, improve problem-solving skills and offer understandable learning. Puzzles increase students' motivation and self-confidence by turning complex concepts into a hobby. In the literature, studies investigating the learning situation with puzzles have examined undergraduate students in different sciences. Even though there are different disciplines, undergraduate students' efforts to search for the right answer, their self-confidence in finding the right answer, and their involvement in the active learning process rather than passive memorization reveal the increase in their knowledge levels. It has been observed that the teaching method with puzzles not only facilitates learning, but also guides students to better recognize their knowledge gaps and weaknesses. Considering nursing education, it is obvious that teaching concepts encountered for the first time with puzzles by providing an active environment in the classroom will increase students' motivation and knowledge level. Despite research conducted with different disciplines in the literature, there are few studies examining the effect of puzzles on the level of learning concepts related to the nursing profession. In this research, the concepts of vital signs, which have an important place in both the student life and professional life of first-year nursing students, will be discussed. An active and fun environment will be provided to students with puzzles on the subjects of respiration, pulse and blood pressure, where students have difficulty in learning the conceptual structure. In this context, it is predicted that the education provided with puzzles will contribute positively to the knowledge level of the students.

A pre-test will be given to all groups before the theoretical lesson on vital signs. Afterwards, the students in the experimental group will apply puzzles for two weeks (12-27/11/2023). Afterwards, final tests will be performed. The work will continue until 10/12/2023.

Control group students will be educated only during the normal course. The research will be conducted with first-year students of Bilecik Şeyh Edebali University Nursing Department.
Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
Participants (N=4854) will be recruited through community partners, at events and using social marketing campaigns including advertisements, referrals from other participants, social media, and a web based educational website (Web-Ed). After establishing eligibility, written informed consent will be obtained. Subjects will complete a survey and provide a urine specimen for chlamydia (Ct) and gonorrhea (GC) testing and will provide their preferred contact information in order to be contacted about their test results. The testing laboratory will report positive results per LA hygiene code LAC 51:II.105: http://ldh.la.gov/assets/oph/Center-PHCH/Center-CH/infectious-epi/Surveillance/sanitarycode.pdf. Tulane study staff will contact participants to inform them of their results. If the participant tests positive for Ct and/or GC, the subject will be offered expedited treatment for the subject and the subject's recent sex partners. The subject may choose to pick up medication at a local pharmacy or medication can be mailed to the subject. Staff will also ask the participant to contact his partner(s) and provide them with the Check It staff's contact information so that staff can let the partner know that they have been exposed to an infection and offer the subject's sexual partner expedited treatment options if the participant did not already provide the subject's sexual partners with that information. No information provided by the participant will be shared with his partners. The study will cover the cost of the medications for subjects who test positive for either or both organisms and their sexual partners. Three months after treatment, male subjects who were positive will be asked to be re-screened and if positive, staff will conduct similar expedited treatment and partner services. Any subject who provides consent for annual testing reminders will be reminded using their preferred method of contact.
The invention relates to the field of traditional Chinese medicines and discloses a traditional Chinese medicine composition as well as a preparation method and application thereof. The traditional Chinese medicine composition disclosed by the invention is prepared from 4-12 parts of ganoderma lucidum, 2-5 parts of rhizoma gastrodiae, 3-7 parts of morinda root, 2-5 parts of astragalus root and 3-8 parts of pseudo-ginseng. The traditional Chinese medicine composition disclosed by the invention is prepared from ganoderma lucidum, rhizoma gastrodiae, morinda root, astragalus root and pseudo-ginseng as raw materials and is simple in formula. The raw materials interact and are synergistic to play a good role in improving memory. The traditional Chinese medicine composition is free of toxic or side effect to a human body, is free of drug dependence, and can be widely used for preparing medicines capable of improving learning and memory abilities and treating senile dementia. The preparation method of the traditional Chinese medicine composition, disclosed by the invention, comprises the steps of mixing the ganoderma lucidum, the rhizoma gastrodiae, the morinda root, the astragalus root and the pseudo-ginseng according to a certain proportion and then extracting with ethanol. Effective ingredients of all the raw materials are farthest kept. The prepared traditional Chinese medicine composition has an obvious effect on improving memory, is simple in operation and is suitable for industrial production.
This study is a single-site, randomized, placebo-controlled clinical trial in which about 24 subjects are expected to complete an 8-week study period. The performance site is Washington University School of Medicine. Even though alirocumab is an approved drug, the investigators consider this to be a phase I trial because it is a physiological study in which the primary endpoint is change in fecal cholesterol excretion and measures of reverse cholesterol transport. It is not a treatment protocol and uses healthy subjects.

Subjects with greater than ideal cholesterol but not taking cholesterol lowering drugs will be studied. All receive whole body cholesterol metabolism tests before and after treatment for 6 weeks with either alirocumab or placebo. Each test takes 2 weeks. On the first day the subjects receive about 35 mg cholesterol-d7 intravenously and blood samples are obtained in order to measure cholesterol turnover rate, pool size, esterification rate, transfer from HDL to LDL and removal from the plasma compartment. Fecal cholesterol excretion and related parameters are measured on days 13 and 14 after a relative steady-state is obtained. During this time the subjects consume a metabolic kitchen diet controlled in cholesterol and phytosterol content and consume oral tracer capsules consisting of cholesterol-d5 and sitostanol-d4. Plasma and stool samples are analyzed by gas chromatography/tandem mass spectrometry to determine daily percent cholesterol excretion from rapidly-mixing body cholesterol pools, fecal cholesterol mass and percent cholesterol absorption. The cholesterol metabolic test is repeated on day 43 and final measurements are made on day 57. Treatment effect, defined as the difference between active and placebo treatments is then calculated. Based on animal data it is expected that alirocumab will increase the efficiency of cholesterol excretion from body pools and the rate of removal of cholesterol ester from plasma.
Design: Prospective, randomized, controlled, open, parallel noninferiority. 440 patients will be randomized to diagnose and follow treatment based on the PR or PSG generating four groups: two treated and two untreated with CPAP. The latter did not undergo self-certification home. The monitoring will be 6 months and 4 assessments. Statistical analysis: compare the change of the scale Epworth before and after the intervention between both treatment arms using analysis of covariance. The premise is non-inferiority of -1.6 at the lower limit of 95%. Secondary variables were analyzed by independent means differences (or nonparametric equivalent) or Chi2 for dichotomous variables. Cost-effectiveness: the costs generated by the two methods will be measured against the effectiveness of the primary endpoint using Bayesian techniques
PURPOSE: To provide a new compd. having excellent long-term duration and useful as an antiparasitic agent and anthelmintic.  
     CONSTITUTION: This compd. is expressed by formula I, wherein R is sec-butyl or isopropyl, and the compd. is, for example, 13β-O-methoxymethyl-22,23- dihydroavermectin BIa/BIb aglycone. The compd. of formula I is obtd. by allowing an avermectin aglycone expressed by formula II to react with a halomethyl ether expressed by CH 3 OCH 2 Cl, especially chloromethyl methyl ether in the presence of a base (e.g. triethylamine) in an anhydrous aprotic solvent (e.g. methylene chloride) at 10 to 120°C for 12 to 24 hours. The avermectin is obtd. by isolating from a fermentation soln. of Streptomyces avermitilis or its deriv. 
     COPYRIGHT: (C)1993,JPO
A composition containing food products and different addi-tives, treated under the effect of an outside power source. As food products said composition contains table salt, sugar and honey in different ratios. Sometimes instead of table salt use is made of sea salt. The con-tent of main ingredients in g/l is as follows: table salt or sea salt in an amount of 1 to 400 g/l, sugar in an amount of 1 to 3000 g/l and honey in an amount of 1 to 6000 g/l. As additives use is made of alkaline or alkali each metal chlorides or carbonates or sea salt or mixture of these compounds in an amount of 320 g/l. As additives use is made also of microelements in the form of copper, molybdenum, manganese, iron, cobalt and nickel chlorides or carbonates in an amount of 1 to 4 g/l. A method com-prising the step of treating the composition with electric current whose length of pulses is in a range of from 1x10-8 to 1 second, with a rate of voltage pulse rise in a range of from 1x10-8 to 1x10 13 V/s and on-off time ratio in a range of from 1 to 10 4 with the electric field inten-sity between electrodes in a range of from 10 to 9x10 4 V/cm. Sometimes the electric pulses are preconverted into magnetic, electromagnetic, light or acoustic pulses.
Heart failure (HF) remains prevalent in patients who survived myocardial infarction (MI). Despite the accessibility of the primary percutaneous coronary intervention and medications that alleviate ventricular remodeling with functional improvement, there is an urgent need for clinicians and basic scientists to further reveal the mechanisms behind post-MI HF as well as investigate earlier and more efficient treatment after MI. Growing numbers of studies have highlighted the crucial role of macrophages in cardiac repair and remodeling following MI, and timely intervention targeting the immune response via macrophages may represent a promising therapeutic avenue. Recently, technology such as single-cell sequencing has provided us with an updated and in-depth understanding of the role of macrophages in MI. Meanwhile, the development of biomaterials has made it possible for macrophage-targeted therapy. Thus, an overall and thorough understanding of the role of macrophages in post-MI HF and the current development status of macrophage-based therapy will assist in the further study and development of macrophage-targeted treatment for post-infarction cardiac remodeling. This review synthesizes the spatiotemporal dynamics, function, mechanism and signaling of macrophages in the process of HF after MI, as well as discusses the emerging bio-materials and possible therapeutic agents targeting macrophages for post-MI HF.
Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and/or biopsy and collection of blood on study.
Chronic kidney disease is the loss of renal function that can occur from aging or through a myriad of other disease states. Rising serum concentrations of kynurenine, a tryptophan metabolite, have been shown to correlate with increasing severity of chronic kidney disease. This study used chronic intravenous infusion in conscious male Sprague-Dawley rats to test the hypothesis that kynurenine can induce renal damage and promote alterations in blood pressure, heart rate, and decreased renal function. We found that kynurenine infusion increased mean arterial pressure, increased the maximum and minimum range of heart rate, decreased glomerular filtration rate, and induced kidney damage in a dose-dependent manner. This study shows that kynurenine infusion can promote kidney disease in healthy, young rats, implying that the increase in kynurenine levels associated with chronic kidney disease may establish a feed-forward mechanism that exacerbates the loss of renal function.NEW & NOTEWORTHY In humans, an elevated serum concentration of kynurenine has long been associated with negative outcomes in various disease states as well as in aging. However, it has been unknown whether these increased kynurenine levels are mediating the disorders or simply associated with them. This study shows that chronically infusing kynurenine can contribute to the development of hypertension and kidney impairment. The mechanism of this action remains to be determined in future studies.
Psoriasis is characterized by excessive angiogenesis, with increased distortion and dilation of the dermal blood vessels. These vascular alterations are ascribed, at least in part, to the changes in dermal microvascular endothelial cell functions. However, despite the recognition of vascular normalization as an emerging strategy for the treatment of psoriasis, in-depth studies of human dermal microvascular endothelial cells (HDMECs) have been missing. The difficulty of isolation and culture of HDMECs has impeded the study of endothelial dysfunction in psoriasis. Researchers have done a great deal of work to study the abnormal characteristics of keratinocytes, fibroblasts, and leukocytes in psoriatic skin tissue. Recently, with successful isolation of HDMECs from psoriasis, great progress has been made in the elucidation of the pathogenic role of these cells in psoriasis. It is of great therapeutic significance to study the molecular mechanism of HDMECs in psoriasis. We review here the abnormalities of HDMECs in psoriasis.
Improved methods for transdermal transport of drug formulations are described herein. Formulations designed to enhance transport of therapeutic levels of topically applied drugs into the systemic circulation, methods of making the formulations are also described herein. The formulations contain at least one active agent to be delivered and at least one skin permeation enhancer in a polymeric hydrogel, and optional additional excipients. Methods for enhancing transport of formulations into and through the skin include: (a) pretreatment of the skin with a hydrating solution, (b) physical permeation of the stratum corneum by low frequency ultrasound (administered by a sono-permeation device, such as SONOPREP®, available from Sontra Medical Corporation, Franklin, MA), (c) topical application of a formulation containing the bioactive molecule, and optionally (d) application of an electric potential difference that forces ionized drugs through the skin. Optionally, the formulation contains permeation-enhancing agents. The method may be used with the formulations described herein or with other formulations for topical administration. In a preferred embodiment, the active agent to be delivered is a drug. Preferably the drug is a local anesthetic, such as lidocaine.
An orally disintegrating Oseltamivir pill for treating influenza in infants and children and preparation method therefor. The percentages by weight of the components of the orally disintegrating pill are as follows: 10-40% of taste-masking pellets, 20-80% of filler, 1-6% of binder, 2-10% of disintegrant, 0-5% of flavoring agent, and 0.5%-2.5% of lubricant. A taste-masking pellet consists of a pellet core containing medicine and a coating layer. The medicine in the pellet core is Oseltamivir or a pharmaceutically acceptable salt thereof, and accounts for 10%-40% of the total pellet weight. The material for the coating layer is polyacrylic acid resin IV and accounts for 1%-50% of the total pellet weight. The diameter of a pellet ranges from 0.10-0.50 mm.
This is a randomized, placebo-controlled, double-blinded crossover study to test the following hypothesis: In mid- to late pubertal girls with hyperandrogenism (HA), acute progesterone suppression of waking LH pulse frequency is greater after 2 weeks of spironolactone pretreatment compared to after 2 weeks of placebo pretreatment. We will only study mid- to late pubertal girls with HA (i.e., girls who would be candidates for therapeutic spironolactone use). Subjects will complete two 18-hour Clinical Research Unit (CRU) admissions in separate menstrual cycles. Subjects will be randomized to be pretreated for 2 weeks with either oral spironolactone (50 mg twice daily) or placebo prior to the first CRU admission. Immediately before and during each CRU admission, oral micronized progesterone (0.8 mg/kg/dose) will be given at 0700, 1500, 2300, and 0700 h. During each CRU admission, blood will be obtained every 10 minutes through an indwelling iv catheter from 1800 to 1200 h. This will allow full characterization of pulsatile LH secretion in addition to other hormone measurements. Formal polysomnography will be performed during CRU admissions. A second CRU admission (performed at least 2 months later given blood withdrawal limits) will be identical to the first except that placebo pretreatment will exchanged for spironolactone pretreatment or vice versa (treatment crossover). The primary endpoint is LH pulse frequency while awake. (LH pulse frequency while asleep is an important secondary endpoint.) The wake LH pulse frequency data from the spironolactone and placebo admissions will be analyzed via a hierarchical linear mixed model (HLMM). The admission (spironolactone vs. placebo) will represent the fixed effect factor of the HLMM. Random effects will be utilized to account for the hierarchical variance-covariance structure of the two-period cross-over design. Wake LH pulse frequency in response to exogenous progesterone will be compared between the spironolactone admission and the placebo admission via a linear contrast of the HLMM least squares LH pulse frequency means. A similar analysis will be performed for sleep-related LH pulse frequency. Using published and preliminary data, we determined that, if 16 mid- to late pubertal girls with HA complete both admissions, we should have at least an 80% chance of detecting a 0.35 pulse/hour mean within-subject difference in wake LH pulse frequency between the spironolactone and placebo admissions with a two-sided false positive rejection rate of no more than 0.05.